Target attainment and pharmacokinetics of cefotaxime in critically ill patients undergoing continuous kidney replacement therapy.
André WieringaPeter G J Ter HorstGertjan H J WagenvoortAnnemieke DijkstraAlan AbdullaJasper J HaringmanBirgit C P KochPublished in: The Journal of antimicrobial chemotherapy (2022)
We conclude that cefotaxime 1000 mg 3-4 times daily gives adequate plasma concentrations in patients with anuria or oliguria undergoing CKRT. The 1000 mg four times daily dosage is recommended in patients undergoing CKRT with partially preserved renal function to achieve the target.